Collaboration Agreements Schedule of Accounts Receivable and Deferred Revenue Information - Teva Collaboration (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Accounts receivable, net (recorded within Prepaid expenses and other current assets)	$ 163,599	$ 224,972
Teva Pharmaceuticals Collaboration Agreement [Member]
Disaggregation of Revenue [Line Items]
Accounts receivable, net (recorded within Prepaid expenses and other current assets)	35,504	71,297
Deferred revenue	$ 194,564	$ 197,357

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Name:	us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant